Investment Rating - The report does not explicitly state an investment rating for the interleukin industry Core Insights - The interleukin family consists of various cytokines that play significant roles in immune regulation, inflammation, and cancer, with many related drugs and clinical pipelines in development [4][5] - The IL-12 and IL-23 cytokines are crucial in immune modulation and have become important therapeutic targets for autoimmune diseases such as psoriasis and Crohn's disease [9][10] - The market for IL-4Rα drugs in allergic diseases is expanding, with two main drugs approved in China for treating allergic asthma and other conditions [16] - IL-1β inhibitors are gaining traction in gout treatment, with a notable increase in patient numbers projected for high uric acid levels and gout by 2030 [23][25] - Artificial intelligence is enhancing drug development processes across various stages, significantly reducing the time required for drug discovery and optimization [31][32] Summary by Sections Interleukin Family Overview - The interleukin family includes multiple members categorized into several groups, each with distinct roles in immune response and disease [3][4] - Key interleukins such as IL-1, IL-2, IL-6, IL-10, and IL-17 are involved in autoimmune and inflammatory diseases, with existing drugs and clinical pipelines targeting these cytokines [5] Market Status of IL-12/IL-23 - Several drugs targeting IL-12 and IL-23 have been approved for treating autoimmune diseases, with notable examples including Ustekinumab and Guselkumab [8][10] - The first fully human monoclonal antibody targeting IL-12/IL-23, Iroquois, is set to launch in 2025 for moderate to severe plaque psoriasis [10] IL-4 in Allergic Diseases - Two IL-4Rα drugs have been approved in China for allergic diseases, with Dupilumab included in the national medical insurance list [16] - The report outlines ongoing clinical trials for additional IL-4Rα therapies targeting various allergic conditions [17] IL-1β Inhibitors in Gout Treatment - The report highlights the increasing prevalence of high uric acid and gout, with projections indicating significant growth in patient numbers by 2030 [21][23] - The first IL-1β monoclonal antibody, Canakinumab, has been approved for gout treatment, with a projected global sales figure of $1.5 billion by 2024 [25] Role of Artificial Intelligence in Drug Development - AI is transforming drug discovery by streamlining processes and improving efficiency, reducing the time for lead compound optimization from approximately 65 months to 30 months [32] - The integration of AI in drug development enhances the accuracy of personalized medicine and accelerates the identification of effective drug candidates [31][32]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of May 11, 2025 [1]. Core Insights - The A-share innovative drug sector saw a weekly increase of 2.33%, outperforming the CSI 300 index by 0.33 percentage points, while the biopharmaceutical sector rose by 0.75% [2][17]. - In the past six months, the A-share innovative drug sector has cumulatively increased by 5.43%, outperforming the CSI 300 index by 9.13 percentage points, whereas the biopharmaceutical sector has decreased by 10.55% [2][17]. - The Hong Kong innovative drug sector experienced a decline of 2.14%, underperforming the Hang Seng Index by 3.75 percentage points, with a cumulative increase of 22.08% over the past six months [2][20]. - The XBI index in the US fell by 8.59% this week, with a cumulative decline of 22.72% over the past six months [2][23]. Summary by Sections Domestic Key Innovative Drug Progress - In May, one new drug was approved for market launch in China, with no new indications approved [3][41]. Overseas Key Innovative Drug Progress - In May, there were no NDA or BLA approvals in the US, Europe, or Japan for innovative drugs [4][45]. Global Key Innovative Drug Transaction Progress - A total of 12 key transactions occurred globally this week, with one disclosed transaction amounting to 415 million USD between Alchemab Therapeutics and Eli Lilly [5]. Market Performance - The report indicates that 39 stocks in the innovative drug sector rose while 67 fell during the week, with the top gainers being HaiChuang Pharmaceutical-U (22.76%), Changchun High-tech (8.99%), and Zhongsheng Pharmaceutical (8.98%) [2][16]. - The top decliners included Fuhong Hanlin (-12.64%), Connaught-B (-12.40%), and Boan Biotechnology (-11.77%) [2][16]. Clinical Trials and Approvals - In May, there were 23 newly announced clinical trials in China, including 17 in BE/I phase, 4 in II phase, and 2 in III phase [31].